Research programme: cancer and CNS disorder therapeutics - Angiochem

Drug Profile

Research programme: cancer and CNS disorder therapeutics - Angiochem

Alternative Names: ANG 3201; ANG-1007; ANG-1009; ANG-1011; ANG-2002; ANG-2004; ANG-2008; ANG-3101; ANG-3202; ANG-4043; Angiopep-antibody-drug conjugate - Angiochem

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AngioChem
  • Class Drug conjugates; Monoclonal antibodies; Peptides; Small molecules
  • Mechanism of Action Brain derived neurotrophic factor modulators; DNA intercalators; ERBB 2 receptor antagonists; Glucagon like peptide 1 receptor agonists; Immunomodulators; Leptin receptor modulators; Neurotensin receptor modulators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer
  • No development reported Brain metastases; Pain
  • Discontinued Brain cancer; Diabetes mellitus; Neurological disorders; Obesity; Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain metastases in Canada (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in Canada
  • 08 Sep 2016 Early research in Cancer in Canada (Parenteral) before September 2016 (Angiochem Pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top